Autor: |
Lucas Guillo, Fanny Grimaud, Fanny Houser, Caroline Prost, Elisabeth Jouve, Cécile Philandrianos, Maxime Abellan, Julie Veran, Carine Visee, Laura Beyer-Berjot, Ariadne Desjeux, Françoise Dignat-George, Marc Leone, Jean-Charles Grimaud, Florence Sabatier, Mélanie Serrero, Jérémy Magalon |
Jazyk: |
angličtina |
Rok vydání: |
2022 |
Předmět: |
|
Zdroj: |
Stem Cell Research & Therapy, Vol 13, Iss 1, Pp 1-6 (2022) |
Druh dokumentu: |
article |
ISSN: |
1757-6512 |
DOI: |
10.1186/s13287-022-02738-x |
Popis: |
Abstract Perianal fistulas in Crohn's disease are frequent and disabling, with a major impact on patients' quality of life. Cell-based therapy using mesenchymal stem cells represents new hope for these patients, but long-term efficacy remains challenging. In a pilot study, including patients with refractory complex perianal fistulas, autologous adipose-derived stromal vascular fraction (ADSVF) combined with microfat achieved combined remission in 60% of cases, with a good safety profile at 1 year. The purpose of this study is to assess whether these results were maintained at longer term. The safety and efficacy data of the ten patients were evaluated retrospectively 3 years after injection on the basis of clinical and radiological data. MRI were analysed according to the MAGNIFI-CD score. No adverse event was attributed to the experimental stem-cell treatment. Combined remission was achieved in 7 patients (70%) and associated with a significant improvement in the MAGNIFI-CD MRI score. In conclusion, the safety and efficacy of ADSVF and microfat injection in Crohn's disease fistulas were maintained at 3 years, demonstrating that this innovative strategy is effective in producing a long-lasting healing effect. The ongoing multicentre randomized placebo-controlled trial (NCT04010526) will be helpful to define the place for this approach in the current therapeutic arsenal. |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|
Nepřihlášeným uživatelům se plný text nezobrazuje |
K zobrazení výsledku je třeba se přihlásit.
|